Eicosanoid-dependent cancer cachexia and wasting
- 1 May 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 5 (3) , 241-248
- https://doi.org/10.1097/00075197-200205000-00002
Abstract
The reversal of catabolic processes remains a significant challenge related, in part, to their complexity and our incomplete understanding of the mechanisms involved. The eicosanoids are key players in the inflammatory process and have been implicated in the process of cancer cachexia. They are unsaturated C20 fatty acids which can be separated into two main groups: the lipoxygenase products including leukotrienes and lipoxins, and the prostanoids including prostaglandins, prostacyclin and thromboxane. This review examines the biology of the eicosanoids and the evidence of a role for the eicosanoids in cancer cachexia and wasting.Keywords
This publication has 49 references indexed in Scilit:
- Prostaglandins and Leukotrienes: Advances in Eicosanoid BiologyScience, 2001
- Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF)British Journal of Cancer, 2001
- Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanesJournal of Clinical Investigation, 2001
- Inflammation and cancer: back to Virchow?The Lancet, 2001
- Proteolysis‐inducing factor regulates hepatic gene expression via the transcription factors NF‐κΒ and STAT3The FASEB Journal, 2001
- A polymorphism of the interleukin-1 β gene influences survival in pancreatic cancerBritish Journal of Cancer, 2000
- Metabolic abnormalities in cachexia and anorexiaNutrition, 2000
- CachexiaAnnals of Internal Medicine, 2000
- Regulation of skeletal-muscle–protein turnover in cancer-associated cachexiaNutrition, 2000
- Liver export protein synthetic rates are increased by oral meal feeding in weight-losing cancer patientsAmerican Journal of Physiology-Endocrinology and Metabolism, 2000